Intact and cleaved forms of the urokinase receptor enhance discrimination of cancer from non-malignant conditions in patients presenting with symptoms related to colorectal cancer

Background: Colorectal cancer (CRC) is a leading cause of cancer-related morbidity and mortality in developed countries. It is known that early detection results in improved survival, and consequently there is a need for improved diagnostic tools in CRC. The plasma level of soluble urokinase plasmin...

Full description

Saved in:
Bibliographic Details
Published in:British journal of cancer 2009-09, Vol.101 (6), p.992-997
Main Authors: Lomholt, A F, Høyer-Hansen, G, Nielsen, H J, Christensen, I J
Format: Article
Language:English
Subjects:
Adenocarcinoma - diagnosis
Adult
Aged
Aged, 80 and over
Biomedical and Life Sciences
Biomedicine
Cancer Research
Case-Control Studies
Colonoscopy
Colorectal cancer
Colorectal Neoplasms - blood
Colorectal Neoplasms - diagnosis
Drug Resistance
Epidemiology
Female
Fluorescent Antibody Technique
Humans
Industrialized nations
Male
Medical prognosis
Medical research
Middle Aged
Molecular Diagnostics
Molecular Medicine
Mortality
Oncology
Receptors, Urokinase Plasminogen Activator - blood
Serology
Tumors
Citations: Items that this one cites
Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:Background: Colorectal cancer (CRC) is a leading cause of cancer-related morbidity and mortality in developed countries. It is known that early detection results in improved survival, and consequently there is a need for improved diagnostic tools in CRC. The plasma level of soluble urokinase plasminogen activator receptor (suPAR) was proposed as a marker in CRC patients. This study was undertaken to evaluate the individual molecular forms of suPAR as discriminators in a group of patients undergoing endoscopical examination following symptoms related to colorectal cancer. Methods: In a case–control study comprising 308 patients undergoing endoscopical examination following CRC-related symptoms, 77 CRC patients with adenocarcinoma were age and gender matched to: 77 patients with adenomas; 77 with other non-malignant findings, and 77 with no findings. The different uPAR forms were measured in citrate plasma collected before endoscopical examination, using three different Time Resolved – Fluorescence Immuno Assays (TR-FIA's). Results: All soluble uPAR forms were found to be significantly higher in cancer patients than in patients presenting with other non-malignant findings; uPAR(I) P =0.0006, suPAR(I–III) P
ISSN:0007-0920
1532-1827
DOI:10.1038/sj.bjc.6605228